European Food Safety Authority: A playing field for the biotech industry

From Powerbase
Revision as of 00:43, 13 January 2013 by Lucy Brown (talk | contribs)
Jump to: navigation, search

Back to GMWatch Portal

Excerpts from the 2010 Testbiotech report European Food Safety Authority: A playing field for the biotech industry are reproduced below and referenced elsewhere across the GMWatch Portal. The original report is available online at Testbiotech or can be downloaded directly. In summary, the report investigates conflicts of interest within the GMO Panel membership to demonstrate how the Panel's relationship with the biotech industry - and in particular via the influence of a task force of the International Life Sciences Institute (ILSI) - resulted in comparative assessment being taken as the starting point in the EFSA guidelines on risk assessment of genetically engineered plants. Comparative assessment, an approach to risk assessment which assumes equivalence between conventional breeding and genetic engineering, has serious implications for the scientific rigour of research into the risks of genetically engineered plants. The authors of the report highlight the potential for further problems given the fact that the databank for such research was set up by the ILSI - an arrangement which 'does not appear to provide adequate protection from targeted manipulation by industry'. Additionally, the authors found that a document published by the EFSA to explain why feeding trials are not required to test for potential health impacts of genetically engineered plants 'was partially plagiarized from an ILSI paper'. The authors suggest that it is 'likely this is only the tip of the iceberg'.[1]

The Testbiotech report explains that risk assessment required by EU regulations is premised on the precautionary principle (Directive 2001/18, see Regulation 1829/2003 on genetically modified food and feed) and should therefore be designed to ensure safety for consumers and environment. The EFSA is tasked with 'the practical application of these regulations in the context of market applications'. Led by Suzy Renckens, the GMO Unit was established to oversee the GMO Panel, an expert panel originally chaired by Harry Kuiper of the RIKILT research institute at Wageningen UR. Risk assessment guidelines were published by the Panel in 2004, followed by further documents addressing other areas of risk assessment including environmental risk assessment, animal feeding trials, allergenicity risk and monitoring.[2] Testbiotech cite an EU Commission report from 2006, observing that 'There has been a lot of criticism from various stakeholders that the work of EFSA is inadequate to fulfil EU requirements.' The authors explain how reports prepared by the GMO Panel have additionally 'failed to gain necessary majorities in the EU Council voting'.[2]

The Testbiotech report identifies the International Life Sciences Institute (ILSI) and the former GMO Panel chair, Harry Kuiper, as the 'most relevant drivers' in terms of industry influence on EFSA guidelines, as will be outlined in more detail below.[2]

How the ILSI impacts the EFSA risk assessment of genetically engineered plants

The authors of the Testbiotech report argue that 'The collaboration between ILSI and the GMO Panel has had a marked effect on EFSA,' referencing the claims of the ILSI itself as to the impact of their task force on EFSA guidelines for risk assessment.[1]

The ILSI Task Force

ILSI, EFSA and the concept of Comparative Assessmnet

Further cooperation between ILSI and EFSA

Resources

Notes

  1. 1.0 1.1 Testbiotech (2010), "European Food Safety Authority: A playing field for the biotech industry," Testbiotech report, p2, accessed 9 January 2013.
  2. 2.0 2.1 2.2 Testbiotech (2010), "European Food Safety Authority: A playing field for the biotech industry," Testbiotech report, p3, accessed 9 January 2013.

Back to GMWatch Portal